Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart.
Platel D, Bonoron-Adèle S, Robert J. Platel D, et al. Among authors: robert j. Pharmacol Toxicol. 2001 May;88(5):250-4. doi: 10.1034/j.1600-0773.2001.d01-112.x. Pharmacol Toxicol. 2001. PMID: 11393585
Clinical pharmacokinetics of epirubicin.
Robert J. Robert J. Clin Pharmacokinet. 1994 Jun;26(6):428-38. doi: 10.2165/00003088-199426060-00002. Clin Pharmacokinet. 1994. PMID: 8070217 Review.
Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture.
Bennis S, Chapey C, Couvreur P, Robert J. Bennis S, et al. Among authors: robert j. Eur J Cancer. 1994;30A(1):89-93. doi: 10.1016/s0959-8049(05)80025-5. Eur J Cancer. 1994. PMID: 8142172
Metabolism of methoxymorpholino-doxorubicin in rat, dog and monkey liver microsomes: comparison with human microsomes.
Beulz-Riche D, Robert J, Menard C, Ratanasavanh D. Beulz-Riche D, et al. Among authors: robert j. Fundam Clin Pharmacol. 2001 Dec;15(6):373-8. doi: 10.1046/j.1472-8206.2001.dc053.x. Fundam Clin Pharmacol. 2001. PMID: 11860524
[Pharmacokinetics of pirarubicin (THP-doxorubicin) in patients with cancer].
Robert J, David M, Huet S, Chauvergne J, Monnier A. Robert J, et al. Bull Cancer. 1989;76(8):889-92. Bull Cancer. 1989. PMID: 2620119 French. No abstract available.
Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver.
Ballet F, Vrignaud P, Robert J, Rey C, Poupon R. Ballet F, et al. Among authors: robert j. Cancer Chemother Pharmacol. 1987;19(3):240-5. doi: 10.1007/BF00252979. Cancer Chemother Pharmacol. 1987. PMID: 3581417
Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities.
Canal P, Robert J, Ramon M, Baurain R, Tresca P, de Forni M, Marty M, Pujade-Lauraine E, Bugat R, Magis A, et al. Canal P, et al. Among authors: robert j. Clin Pharmacol Ther. 1992 Mar;51(3):249-59. doi: 10.1038/clpt.1992.19. Clin Pharmacol Ther. 1992. PMID: 1544285 Clinical Trial.
Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
Platel D, Pouna P, Bonoron-Adèle S, Robert J. Platel D, et al. Among authors: robert j. Toxicol Appl Pharmacol. 2000 Mar 1;163(2):135-40. doi: 10.1006/taap.1999.8847. Toxicol Appl Pharmacol. 2000. PMID: 10698671
Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model.
Platel D, Pouna P, Bonoron-Adèle S, Robert J. Platel D, et al. Among authors: robert j. Anticancer Drugs. 1999 Aug;10(7):671-6. doi: 10.1097/00001813-199908000-00007. Anticancer Drugs. 1999. PMID: 10507317
Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
Bennis S, Faure P, Chapey C, Hu YP, Fourche J, El Yamani J, Robert J. Bennis S, et al. Among authors: robert j. Anticancer Drugs. 1997 Jul;8(6):610-7. doi: 10.1097/00001813-199707000-00009. Anticancer Drugs. 1997. PMID: 9300576
Feedback